Treatment strategy of peripheral arterial diseases with Rotarex
10.3760/cma.j.cn113855-20200929-00754
- VernacularTitle:Rotarex在外周动脉疾病中的应用
- Author:
Hao LIU
1
;
Shuai JU
;
Bin CHEN
;
Junhao JIANG
;
Yun SHI
;
Tao MA
;
Changpo LIN
;
Daqiao GUO
;
Xin XU
;
Zhihui DONG
;
Weiguo FU
Author Information
1. 复旦大学附属中山医院血管外科，上海 200030
- Keywords:
Arterial occlusion disease;
Vascular surgical procedures;
Percutaneous mechanical thrombectomy
- From:
Chinese Journal of General Surgery
2021;36(7):516-519
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the effect of Rotarex in peripheral arterial disease (PAD).Methods:The clinical data of 90 PAD patients treated with Rotarex from Aug 2018 to Feb 2020 were retrospectively analyzed.Results:Among the 90 patients, 45 patients had atherosclerotic obliterans complicated with acute thrombosis (ASOCAT), 27 patients had graft restenosis or reocclusion, 16 patients had primary or embolism-induced thrombosis, 2 patients had traumatic or iatrogenic arterial occlusion. Except for 2 patients undergoing hybrid surgery, 88 patients underwent endovascular treatment. Two patients died perioperatively. Within 12 months follow-up, 2 patients died, 4 patients underwent major amputation, target arteries of 10 patients were re-stenosed or re-occluded and 5 patients were lost to follow-up. Compared with the preoperative ankle-branchial index (ABI), significant increase was observed in the 12-month ABI (0.80±0.22 vs. 0.43±0.16, P<0.01). The 12-month restenosis/re-occlusion-free rate was 82.7%, and the 12-month major amputation-free survival (MAFS) was 91.6%. Conclusion:For PAD patients, acceptable outcomes can be achieved with reasonable use of Rotarex for debulking, combined with balloon, stent and other techniques to correct the residual lesions.
